Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace
Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more) Full Story
athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
Forget Food and Fuel: America's Corn Is Worth $... 9 hr One way or another 2
Hillsborough in hunt for up to 700 Johnson & Jo... Mar 1 HumanSpirit 1
Singapore, Canada researchers make longer-lasti... Feb 25 Solarman 1
Merck grants free license for pediatric HIV drug Feb 24 VACCINES MAIM KILL 1
Some newer birth control pills need ban: U.S. g... (Feb '07) Feb 18 lucy 16
Massive vaccine cover-up confirmed: Secret docu... Feb 14 friend 9
Merck senior management tried to pay off its ow... Feb 13 followthecrowdoff... 1
More from around the web